Omalizumab is a biological therapy for severe allergic asthma. Omalizumab is a glycosylated humanized IgG1k monoclonal antibody that specifically binds to circulating immunoglobulin E (IgE). It has a biological half-life of 5 days. Omalizumab leads to a reduced response of the proinflammatory mediators and substantially reduces IgE activity, targeting allergen sensitization and allergic inflammation [1] . Several side effects have been described for the use of omalizumab. The most severe side effect is anaphylactic shock, occurring in one or two patients per 1000 [2] . In this case report, myasthenia gravis (MG) is proposed as a probable side effect of treatment with omalizumab. MG is the clinical manifestation of impaired neuromuscular transmission due to an autoimmune reaction against the acetylcholine receptor (AChR), or muscle-specific tyrosine kinase (MuSK), or possibly other rarer targets. Lipoprotein receptor-related protein 4 (LRP4)-specific antibody is described in some patients with double-seronegative MG [3] . MG caused by acquired immunological or genetic abnormalities has a progressive course. Prognosis for MG is generally fair as long as there is no disease progression to involve respiratory muscles. Of patients who initially present with ocular MG, 85% will develop systemic MG within 2 years of diagnosis.
Our patient is a 63-year-old, non-smoking male, receiving treatment for severe allergic asthma, which he has been suffering from since childhood. His medical history also notes maxillary sinus polypectomy and laparoscopic cholecystectomy. He once suffered exacerbation of his asthma after being given metamizole prior to surgery. The past 7 years he also acquired exceptional nasal symptoms and dyspnoea. After starting omalizumab in 2011, these symptoms improved. Additional medications were salbutamol and fluticasone. He had been on omalizumab 300 mg month À1 for 5 years, when he first noticed diplopia.
The ophthalmologist considered ocular myasthenia gravis and referred him to a neurologist. The physical neurological examination showed strabismus and left-sided ptosis. His symptoms disappeared after discontinuation of omalizumab. Five months later his asthmatic symptoms had worsened and therefore monthly 600 mg omalizumab was initiated. Within 2 months the patient recognized the symptoms of diplopia and decided to stop omalizumab. He had no family or personal history of neurological diseases. At presentation, the physical neurological examination showed progressive strabismus and ptosis and fluctuating ocular muscle paresis, worsening by strain and focusing to the left corner of his eyes, suggestive of ocular myasthenic syndrome. Laboratory tests revealed no abnormal thyroid stimulating hormone and no detectable antibodies to AChR, MuSK and LRP4. IgG against omalizumab was not increased (<12 AE ml À1 ). After [4] . Possibly there is a still unknown autoimmune mechanism in a similar pathogenesis as described in other drug-induced immunologic effects -for example, drug-induced lupus erythematosus, which induces immunologic effector mechanism, probably in a genetically predisposed individual [5] . Also penicillamine and interferon can cause MG development, but the mechanism is not completely understood. Ipilimumab and nivolumab in the treatment of small cell lung cancer are associated with MG [6] .
In conclusion, this case report suggests a reversible side effect of omalizumab with clinical symptoms of ocular MG observed twice after treatment with omalizumab. The pathophysiology of this side effect and possible autoimmune mechanism is not yet clear and still has to be further elucidated.
